Our investors, scientific and clinical advisors are key to our success

In 2012 Karus secured a £25m ($39m) Series B investment led by SV Life Sciences (now SV Health Investors), New Leaf Ventures, Novo A/S and International Biotechnology Trust, who joined existing investors, IP Group and several Business Angels. This investment is being used to advance KA2237 and KA2507 from concept to clinic.